NEJM Publication of PMV Pharma’s Rezatapopt Data Highlights 46% Response Rate in Ovarian Cancer—What’s Next for TP53 Y220C-Mutated Tumors?
Phase 1/2 Data Publish in NEJM—Key Efficacy Metrics Stand Out
PMV Pharmaceuticals (NASDAQ: PMVP) saw its lead candidate, rezatapopt, race into the spotlight after The New England Journal of Medicine (NEJM) published first-in-human clinical data on the therapy’s use in TP53 Y220C-mutated advanced solid tumors. The publication comes on the back of results from the PYNNACLE trial, where heavily pretreated patients received oral rezatapopt, showing meaningful clinical activity and confirming the drug's mechanism of selectively reactivating the p53 protein in cancer cells.
46% Ovarian Cancer Response Rate in Phase 2—A Target in High Unmet Need
The latest pivotal Phase 2 interim data, as of September 2025, show ovarian cancer patients experienced a 46% objective response rate (ORR) (22 out of 48 patients) as measured by RECIST 1.1 criteria. Importantly, this subgroup included patients who were platinum-resistant or refractory, setting a high bar for efficacy. Across all cohorts, ORR stood at 34%, with responses also seen in lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma.
| Indication | Total Patients | Response Rate (ORR) | Median Time to Response (mo) | Median Duration of Response (mo) |
|---|---|---|---|---|
| Ovarian Cancer | 48 | 46% | 1.3 | 8.00 |
| All Cohorts | 103 | 34% | 1.3 | 7.60 |
Strong Early Responses and Manageable Safety Profile Support Regulatory Strategy
Rezatapopt’s median time to response was a rapid 1.3 months, with a median response duration of up to 8.00 months in the ovarian cohort. The drug was generally well tolerated, with infrequent dose-limiting toxicities—an important factor as PMV Pharma moves toward regulatory filings. The company aims to submit a New Drug Application for platinum-resistant/refractory ovarian cancer in early 2027, highlighting ongoing confidence in the data’s robustness.
PMV Pharma’s Precision Approach Targets TP53 Mutations—A Broad Oncology Opportunity
TP53 mutations are found in approximately half of all cancers. Rezatapopt is designed as a first-in-class molecule to selectively bind and reactivate the mutant Y220C pocket in p53, restoring its tumor-suppressing capabilities. With Fast Track designation from the FDA, PMV Pharma appears well positioned to capture a meaningful share of this high-need patient population if upcoming pivotal data remains strong.
Key Takeaways—PMVP at a Crossroads Ahead of 2027 NDA Filing
The NEJM publication validates both the science and commercial thesis for rezatapopt, with specific promise in ovarian cancer. Investors and clinicians will be watching closely as additional Phase 2 data matures and the company advances toward FDA submission. The 46% response rate underscores the drug’s potential—but the path to regulatory approval, commercial adoption, and expanded indications will ultimately depend on confirmatory results and continued tolerability.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI